Just going back to Glucagon. I mean you had commented for maybe Q4 launch. Just wanted to know is this a kit presentation or a vial presentation?
And I mean I'm probably also understanding the market is shifting here , because I think the use of the product is now shifting mostly to diagnostic chains in the US, that's why the vial presentation is probably getting bigger. But I mean would the market size have become different as per your understanding?
Thanks for taking my question. Vinita, you commented on Spiriva AG-, not sure. But any update on the next ANDA filer, when we can see update on the Chinese product Lannett was trying to bring?
And just commenting again on this few pipeline products you mentioned, especially Victoza, S axenda, none of the Indian generics have settled ; whereas we have seen so many MNC companies have already settled with Teva, possibly forming the market later this year. Just trying to assess how competitive this will be in FY '26, and whether it will be meaningfully different, depending upon what device every generic brings.